Is Ocular Therapeutix (OCUL) Pricing Reflect Its Volatile Returns And Rich Sales Multiple?

• If you are trying to work out whether Ocular Therapeutix at around US$8.76 is a bargain or just fairly priced, starting with a clear view of its valuation can help frame your next move.
• The stock has seen mixed returns, with a 14.7% decline over the last 7 days and a 4.4% decline over the last 30 days, while the 1 year return sits at 13.5% and the 3 year return at 76.6%, compared with a 57.6% decline over 5 years.
• Recent market attention on Ocular Therapeutix has focused on its progress as an ophthalmology focused biopharmaceutical company and how its pipeline prospects fit into the broader sector conversation. That backdrop helps explain why investors may be reassessing both the potential and the risks reflected in the current share price.
• On our framework of 6 valuation checks, Ocular Therapeutix currently scores 2 out of 6, as shown by our valuation score. Next, we will walk through the key valuation methods behind that result and finish with a way to put all of these models into a clearer, big picture view.

Ocular Therapeutix scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Ocular Therapeutix Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today’s dollars. It aims to show what the business may be worth based on those cash flows rather than on current market sentiment.

For Ocular Therapeutix, the model used is a 2 Stage Free Cash Flow to Equity approach. On a last twelve month basis, the company reports free cash flow of $210.67 million outflow. Analyst and extrapolated estimates point to a gradual shift, with projected free cash flow of $238.90 million in 2030, and a set of yearly projections between 2026 and 2035 used to build the cash flow curve. All of these figures are in $.

Discounting those projected cash flows back to today produces an estimated intrinsic value of $86.45 per share. Compared with the recent share price of about $8.76, the DCF output suggests the stock trades at a very large discount, with an implied undervaluation of 89.9%.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Ocular Therapeutix is undervalued by 89.9%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ocular Therapeutix.

Approach 2: Ocular Therapeutix Price vs Sales

For companies that are not consistently profitable, earnings based metrics like P/E can be less helpful, so investors often look at revenue instead and use the Price to Sales, or P/S, ratio to compare valuation. A higher P/S usually reflects stronger growth expectations or a perception of lower risk, while a lower P/S can point to more modest growth assumptions or higher perceived risk.

Ocular Therapeutix currently trades on a P/S ratio of 36.71x. This sits well above the Pharmaceuticals industry average P/S of 3.98x and also above the peer group average of 9.30x. On the surface, that gap suggests the market is placing a much higher value on each dollar of Ocular Therapeutix revenue than it does for many peers.

Simply Wall St’s Fair Ratio is a proprietary estimate of what a company’s preferred multiple could reasonably be, after considering factors such as growth outlook, industry, profit margins, market cap and specific risks. For Ocular Therapeutix, the Fair Ratio comes out at 0.19x, which is far below the current 36.71x P/S. Because the Fair Ratio adjusts for the company’s own fundamentals instead of relying only on simple peer or industry comparisons, it can give a more tailored view of value, and on this measure the shares screen as expensive.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Ocular Therapeutix Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way for you to attach a clear story about Ocular Therapeutix to concrete numbers like your fair value estimate and your assumptions for future revenue, earnings and margins.

On Simply Wall St, a Narrative is your own view of how the company’s story could play out. It is linked directly to a forecast and then to a fair value, and it sits inside the Community page where millions of investors share and compare these views.

You can see this in action for Ocular Therapeutix. One bearish Narrative assumes a fair value of US$18.00 with revenue growing around 30.51% and a future P/E of 236.44x. A bullish Narrative works with a fair value of US$31.00, revenue growth of 109.49% and a future P/E of 91.93x. A third, more middle ground view uses a fair value of about US$24.17, revenue growth of 58.87% and a future P/E of 164.64x.

By comparing each Narrative’s fair value with the current share price, you can quickly see how that story would position you as an investor, whether buying, holding or selling. Because these Narratives update when new news or earnings arrive, your view on Ocular Therapeutix can stay aligned with the latest information without you rebuilding every model from scratch.

Do you think there's more to the story for Ocular Therapeutix? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com